Amiodarone and dronedarone: An update

详细信息    查看全文

• 作者：Mate Vamos ; MD ; Stefan H. Hohnloser ; MD ; FACC ; FESC ; FHRS ; ^{hohnloser@em.uni-frankfurt.de" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Atrial fibrillation ; Antiarrhythmic drugs ; Amiodarone ; Dronedarone
• 刊名：Trends in Cardiovascular Medicine
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：26
• 期：7
• 页码：597-602
• 全文大小：800 K

文摘

This article provides a contemporary review of the current role of amiodarone and dronedarone in patients with atrial fibrillation who need to undergo rhythm control therapy for relief of symptoms. Amiodarone is the most widely prescribed antiarrhythmic drug for this indication. Recent findings show that its use is not associated with increased mortality even in patients with advanced structural heart disease. However, its extracardiac side effect profile may limit its widespread use. Dronedarone appears to be a useful drug in patients with paroxysmal or persistent atrial fibrillation. However, the compound cannot be used in patients with heart failure. In permanent atrial fibrillation, dronedarone is likewise contraindicated based on findings from the PALLAS trial.